A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
More news for Thursday, Feb. 1
By
Kimberly Bonvissuto
Feb 01, 2024
Federal standards, employer preparedness plans need improving to protect frontline workers: study … Joint federal agency letter urges utility data access for affordable housing providers … LeadingAge...
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Ultrasound tech could allow for ultrafast Alzheimer’s treatment, study finds
By
Aaron Dorman
Jan 09, 2024
Researchers have found a way to deliver Alzheimer’s drugs faster via focused ultrasound technology, a new study shows.